Skip to Content
Back
Contact Revance
Login
Menu
Aesthetics
Back
Aesthetics
Visit Site
Overview
RHA®
HintMD
Neuromodulator
Neuromodulator Uses
Clinical Highlights
Therapeutics
Back
Therapeutics
Overview
Cervical Dystonia
Upper Limb Spasticity
Plantar Fasciitis
Clinical Highlights
Investors
Back
Investors
LATEST NEWS
Our Latest
December 22, 2020
Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection
All News
Investor Relations
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Analyst Coverage
Investor FAQ
Contact Us
Company
Back
Company
OUR LATEST
Our Latest
December 22, 2020
Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection
Our Latest
Overview
About Revance
Leadership Team
Board of Directors
Partnerships
Investigator Sponsored Trials
Medical Education Grants
Sustainability
Contact Revance
News
Careers
Back
Careers
Overview
Career Opportunities
Culture
Benefits & Perks
facebook
instagram
twitter
linkedin
1222 Demonbreun St
Suite 2000
Nashville, TN 37203
+1 (510) 742-3400
Contact Revance
Login
© Copyright 2021
All Rights Reserved
Terms of Use
Privacy Policy
Home
Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate‐to‐severe nasolabial folds: A 64‐week, prospective, multicenter, controlled, randomized, double‐blind and within‐subject study
Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate‐to‐severe nasolabial folds: A 64‐week, prospective, multicenter, controlled, randomized, double‐blind and within‐subject study
Back to top